Research analysts at StockNews.com began coverage on shares of Core Laboratories (NYSE:CLB – Get Rating) in a report released on Sunday. The brokerage set a “hold” rating on the oil and gas company’s stock.
Other equities analysts also recently issued research reports about the stock. Citigroup boosted their price target on shares of Core Laboratories from $21.00 to $26.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 7th. Bank of America raised Core Laboratories from an “underperform” rating to a “neutral” rating in a research note on Monday, January 9th. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $21.83.
Core Laboratories Stock Performance
NYSE CLB opened at $22.29 on Friday. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.05 and a quick ratio of 1.47. The company has a market cap of $1.04 billion, a P/E ratio of 54.37 and a beta of 2.66. The stock has a 50-day moving average of $23.54 and a two-hundred day moving average of $21.04. Core Laboratories has a 1-year low of $13.19 and a 1-year high of $34.08.
Institutional Trading of Core Laboratories
A number of institutional investors have recently bought and sold shares of the business. Ariel Investments LLC increased its holdings in shares of Core Laboratories by 5.1% in the 1st quarter. Ariel Investments LLC now owns 8,198,544 shares of the oil and gas company’s stock valued at $259,320,000 after acquiring an additional 394,237 shares during the last quarter. BlackRock Inc. increased its stake in Core Laboratories by 2.2% in the first quarter. BlackRock Inc. now owns 5,479,023 shares of the oil and gas company’s stock valued at $173,300,000 after purchasing an additional 116,130 shares during the last quarter. Vanguard Group Inc. raised its holdings in Core Laboratories by 0.9% during the third quarter. Vanguard Group Inc. now owns 5,144,814 shares of the oil and gas company’s stock worth $69,352,000 after purchasing an additional 46,425 shares in the last quarter. Fred Alger Management LLC lifted its position in shares of Core Laboratories by 1.6% during the 3rd quarter. Fred Alger Management LLC now owns 4,089,324 shares of the oil and gas company’s stock worth $55,124,000 after buying an additional 64,734 shares during the last quarter. Finally, Earnest Partners LLC boosted its holdings in shares of Core Laboratories by 7.8% in the 4th quarter. Earnest Partners LLC now owns 3,573,101 shares of the oil and gas company’s stock valued at $72,427,000 after buying an additional 258,817 shares in the last quarter. 97.44% of the stock is owned by hedge funds and other institutional investors.
About Core Laboratories
Core Laboratories NV engages in the provision of proprietary and patented reservoir description, production enhancement, and reservoir management services to the oil and gas industry. It operates through the Reservoir Description segment and Production Enhancement segment. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid, and gas samples and provides analytical and field services to characterize properties of crude oil and petroleum products.
Featured Articles
- Get a free copy of the StockNews.com research report on Core Laboratories (CLB)
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
